Isopropylphenidate

Isopropylphenidate (iPPH; IPPH) is a synthetic stimulant of the substituted phenidate chemical class — a structural analog of methylphenidate (Ritalin) in which the methyl ester is replaced by an isopropyl ester. This modification produces several clinically relevant differences from methylphenidate: notably, isopropylphenidate is not efficiently metabolized by carboxylesterase-1 to a ritalinic acid analog in the presence of ethanol, reducing the ethanol transesterification risk that is a specific concern for methylphenidate and ethylphenidate.

Isopropylphenidate acts as a dopamine and norepinephrine reuptake inhibitor through binding to DAT and NET — the core phenidate-class mechanism — without the releasing agent activity of amphetamines. This produces a characteristically smoother, less "sharp" stimulation than amphetamines, valued by users seeking functional cognitive enhancement without the intensity or cardiovascular activation of releasing agents. Community reports describe it as producing clean focus, moderate motivation enhancement, and mild mood elevation broadly comparable to methylphenidate but with a somewhat longer duration.

The compound gained particular attention in the harm reduction community as the UK Psychoactive Substances Act (2016) scheduled most phenidate RCs, and iPPH was developed partly as a structural modification that might provide a legal path. It subsequently became one of the more widely discussed phenidate alternatives in European harm reduction communities. In vivo rat studies confirm stimulatory effects; in vitro transporter binding characterization has been conducted, giving iPPH slightly more pharmacological documentation than some research chemicals. Nevertheless, formal human pharmacological and long-term safety data remain absent.